Literature DB >> 15173275

Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

Brooke Ratliff, Eric C Dietze, Gregory R Bean, Cassandra Moore, Sam Wanko, Victoria L Seewaldt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15173275     DOI： 10.1093/jnci/djh170

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  5 in total

1.  Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.

Authors:  Hiltrud Brauch; Werner Schroth; Matthew P Goetz; Thomas E Mürdter; Stefan Winter; James N Ingle; Matthias Schwab; Michel Eichelbaum
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

2.  The Discriminatory Value of CYP2D6 Genotyping in Predicting the Dextromethorphan/Dextrorphan Phenotype in Women with Breast Cancer.

Authors:  Andreas Trojan; Athanasios Vergopoulos; Urs Breitenstein; Burkhardt Seifert; Christoph Rageth; Wolfgang Joechle
Journal:  Breast Care (Basel)       Date:  2012-02-20       Impact factor: 2.860

3.  Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen.

Authors:  Timothy L Lash; Deirdre Cronin-Fenton; Thomas P Ahern; Carol L Rosenberg; Kathryn L Lunetta; Rebecca A Silliman; Stephen Hamilton-Dutoit; Jens Peter Garne; Marianne Ewertz; Henrik Toft Sørensen; Lars Pedersen
Journal:  Acta Oncol       Date:  2010-04       Impact factor: 4.089

4.  CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.

Authors:  Timothy L Lash; Deirdre Cronin-Fenton; Thomas P Ahern; Carol L Rosenberg; Kathryn L Lunetta; Rebecca A Silliman; Jens Peter Garne; Henrik Toft Sørensen; Ylva Hellberg; Mariann Christensen; Lars Pedersen; Stephen Hamilton-Dutoit
Journal:  J Natl Cancer Inst       Date:  2011-02-15       Impact factor: 13.506

5.  Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram.

Authors:  T L Lash; L Pedersen; D Cronin-Fenton; T P Ahern; C L Rosenberg; K L Lunetta; R A Silliman; S Hamilton-Dutoit; J P Garne; M Ewertz; H T Sørensen
Journal:  Br J Cancer       Date:  2008-07-29       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.